THE PREVALENCE OF SIDE-EFFECTS WITH REGULAR AND SUSTAINED-RELEASE NICOTINIC-ACID

被引:43
作者
GIBBONS, LW
GONZALEZ, V
GORDON, N
GRUNDY, S
机构
[1] DALLAS HEART GRP,DALLAS,TX
[2] UNIV TEXAS,SW MED SCH,DALLAS,TX
关键词
D O I
10.1016/S0002-9343(99)80185-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: TO document the prevalence and nature of the side effects that occur with the use of regular and sustained-release nicotinic acid in everyday clinical practice. PATIENTS AND METHODS: One hundred and ten patients seen in a private medical clinic who were given 133 separate trials of nicotinic acid during a 5-year period. The occurrence of side effects, particularly those severe enough to warrant discontinuing the drug, were carefully monitored. RESULTS: Forty-three percent of individuals given regular nicotinic acid and 42% of those given sustained-release nicotinic acid were forced to discontinue the medication because of side effects; some of these side effects necessitating discontinuing nicotinic acid did not occur until the patient had been taking the drug for 1 or 2 years. CONCLUSION: Nicotinic acid in both regular and sustained-release forms is a powerful drug when used in doses needed to treat lipid disorders and causes disturbing side effects a very high percentage of the time. No one should use nicotinic acid in these doses without continued careful supervision of a physician.
引用
收藏
页码:378 / 385
页数:8
相关论文
共 11 条
[1]   BENEFICIAL-EFFECTS OF COMBINED COLESTIPOL-NIACIN THERAPY ON CORONARY ATHEROSCLEROSIS AND CORONARY VENOUS BYPASS GRAFTS [J].
BLANKENHORN, DH ;
NESSIM, SA ;
JOHNSON, RL ;
SANMARCO, ME ;
AZEN, SP ;
CASHINHEMPHILL, L .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3233-3240
[2]  
BROWN G, 1990, NEW ENGL J MED, V34, P1289
[3]  
BROWN WV, 1991, DRUG TREATMENT HYPER, P189
[4]  
CARLSON LA, 1988, ACTA MED SCAND, V223, P405
[5]   BENEFICIAL-EFFECTS OF COLESTIPOL-NIACIN ON CORONARY ATHEROSCLEROSIS - A 4-YEAR FOLLOW-UP [J].
CASHINHEMPHILL, L ;
MACK, WJ ;
POGODA, JM ;
SANMARCO, ME ;
AZEN, SP ;
BLANKENHORN, DH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (23) :3013-3017
[6]  
KEENAN JM, 1992, J FAM PRACTICE, V34, P313
[7]   CONTRASTING EFFECTS OF UNMODIFIED AND TIME-RELEASE FORMS OF NIACIN ON LIPOPROTEINS IN HYPERLIPIDEMIC SUBJECTS - CLUES TO MECHANISM OF ACTION OF NIACIN [J].
KNOPP, RH ;
GINSBERG, J ;
ALBERS, JJ ;
HOFF, C ;
OGILVIE, JT ;
WARNICK, GR ;
BURROWS, E ;
RETZLAFF, B ;
POOLE, M .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (07) :642-650
[8]   A COMPARISON OF THE EFFICACY AND TOXIC EFFECTS OF SUSTAINED-RELEASE VS IMMEDIATE-RELEASE NIACIN IN HYPERCHOLESTEROLEMIC PATIENTS [J].
MCKENNEY, JM ;
PROCTOR, JD ;
HARRIS, S ;
CHINCHILI, VM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (09) :672-677
[9]   LIPOPROTEIN RESPONSES TO TREATMENT WITH LOVASTATIN, GEMFIBROZIL, AND NICOTINIC-ACID IN NORMOLIPIDEMIC PATIENTS WITH HYPOALPHALIPOPROTEINEMIA [J].
VEGA, GL ;
GRUNDY, SM .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (01) :73-82
[10]  
1975, JAMA-J AM MED ASSOC, V231, P360